Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene

Journal of the National Cancer Institute

Volumn 99, Issue 18, 2007, Pages 1401-1409

  Pine, Sharon R ^a   Mechanic, Leah E ^a   Ambs, Stefan ^a   Bowman, Elise D ^a   Chanock, Stephen J ^a   Loffredo, Christopher ^b   Shields, Peter G ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN 2; MANNOSE BINDING LECTIN; MBL2 PROTEIN, HUMAN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ALLELE; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; INNATE IMMUNITY; INTERVIEW; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT; SMOKING; STATISTICAL SIGNIFICANCE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; ALLELES; BALTIMORE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAPLOTYPES; HUMANS; IMMUNITY, NATURAL; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESEARCH DESIGN; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 34748878297     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm128     Document Type: Article

References (39)

1. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
3. Liu G, Zhou W, Christiani DC. Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 2005;26:265-72.
4. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, Kim JH, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:885-91.
5. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-203.
6. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003;40:423-9.
7. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency - revisited. Mol Immunol 2003;40:73-84.
8. Baccarelli A, Hou L, Chen J, Lissowska J, El Omar EM, Grillo P, et al. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int J Cancer 2006;119:1970-5.
9. Davies EJ, Snowden N, Hillarby MC, Carthy D, Grennan DM, Thomson W, et al. Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum 1995;38:110-4.
10. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229-32.
11. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001;285:1316-21.
12. Boniotto M, Braida L, Baldas V, Not T, Ventura A, Vatta S, et al. Evidence of a correlation between mannose binding lectin and celiac disease: a model for other autoimmune diseases. J Mol Med 2005;83:308-15.
13. Scudiero O, Nardone G, Omodei D, Tatangelo F, Vitale DF, Salvatore F, et al. A mannose-binding lectin-defective haplotype is a risk factor for gastric cancer. Clin Chem 2006;52:1625-7.
14. Schmiegelow K, Garred P, Lausen B, Andreassen B, Petersen BL, Madsen HO. Increased frequency of mannose-binding lectin insufficiency among children with acute lymphoblastic leukemia. Blood 2002;100:3757-60.
15. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, et al. Mannose-binding protein B allele confers protection against tuberculous meningitis. Pediatr Res 1999;45:459-64.
16. Uguz A, Berber Z, Coskun M, Halide AS, Yegin O. Mannose-binding lectin levels in children with asthma. Pediatr Allergy Immunol 2005;16:231-5.
17. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005;175:541-6.
18. Matsushita M, Miyakawa H, Tanaka A, Hijikata M, Kikuchi K, Fujikawa H, et al. Single nucleotide polymorphisms of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis. J Autoimmun 2001;17:251-7.
19. Garred P, Harboe M, Oettinger T, Koch C, Svejgaard A. Dual role of mannan-binding protein in infections: another case of heterosis? Eur J Immunogenet 1994;21:125-31.
20. Naito H, Ikeda A, Hasegawa K, Oka S, Uemura K, Kawasaki N, et al. Characterization of human serum mannan-binding protein promoter. J Biochem (Tokyo) 1999;126:1004-12.
21. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19(2)209-16.
22. Marrogi AJ, Mechanic LE, Welsh JA, Bowman ED, Khan MA, Enewold L, et al. TP53 mutation spectrum in lung cancer is not different in women and men. Cancer Epidemiol Biomarkers Prev 2005;14:1031-3.
23. Zheng YL, Loffredo CA, Yu Z, Jones RT, Krasna MJ, Alberg AJ, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
24. Zheng YL, Loffredo CA, Alberg AJ, Yu Z, Jones RT, Perlmutter D, et al. Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res 2005;65:9566-73.
25. Bernig T, Boersma BJ, Howe TM, Welch R, Yadavalli S, Staats B, et al. The mannose-binding lectin (MBL2) haplotype and breast cancer: an association study in African American and Caucasian women. Carcinogenesis 2007;28:828-36.
26. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-23.
27. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998;19:589-601.
28. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-6.
29. Maffei G, Brouwer N, Dolman KM, van der Velden U, Roos D, Loos BG. Plasma levels of mannan-binding lectin in relation to periodontitis and smoking. J Periodontol 2005;76:1881-9.
30. Schlapbach LJ, Aebi C, Otth M, Luethy AR, Leibundgut K, Hirt A, et al. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr Blood Cancer 2007;49:11-6.
31. Larsen F, Madsen HO, Sim RB, Koch C, Garred P. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J Biol Chem 2004;279:21302-11.
32. Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 2005;26:1627-33.
33. Chen T, Nines RG, Peschke SM, Kresty LA, Stoner GD. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Cancer Res 2004;64:3714-7.
34. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739-44.
35. Hussain SP, Trivers GE, Hofseth LJ, He P, Shaikh I, Mechanic LE, et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 2004;64:6849-53.
36. Madsen HO, Satz ML, Hogh B, Svejgaard A, Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J Immunol 1998;161:3169-75.
37. Mayilyan KR, Presanis JS, Arnold JN, Sim RB. Discrete MBL-MASP complexes show wide inter-individual variability in concentration: data from UK vs Armenian populations. Int J Immunopathol Pharmacol 2006;19:567-80.
38. Thiel S, Steffensen R, Christensen IJ, Ip WK, Lau YL, Reason IJ, et al. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun 2007;8:154-63.
39. Verma A, Matta A, Shukla NK, Deo SV, Gupta SD, Ralhan R. Clinical significance of mannose-binding lectin-associated serine protease-2 expression in esophageal squamous cell carcinoma. Int J Cancer 2006;118:2930-5.